Rep. Jared Moskowitz Sells STERIS plc (NYSE:STE) Stock

Posted by Brenda Bartman on Sep 3rd, 2026

Representative Jared Moskowitz (Democratic-Florida) recently sold shares of STERIS plc (NYSE:STE). In a filing disclosed on August 27th, the Representative disclosed that they had sold between $1,001 and $15,000 in STERIS stock on July 13th. The trade occurred in the Representative’s “MORGAN STANLEY ACTIVE ASSETS (1)” account.

Representative Jared Moskowitz also recently made the following trade(s):

Sold $1,001 – $15,000 in shares of W.W. Grainger (NYSE:GWW) on 7/13/2026.
Purchased $1,001 – $15,000 in shares of Applied Materials (NASDAQ:AMAT) on 7/13/2026.
Purchased $1,001 – $15,000 in shares of Applied Materials (NASDAQ:AMAT) on 6/18/2026.
Purchased $1,001 – $15,000 in shares of Microsoft (NASDAQ:MSFT) on 6/17/2026.
Purchased $1,001 – $15,000 in shares of HCA Healthcare (NYSE:HCA) on 6/17/2026.
Purchased $1,001 – $15,000 in shares of Home Depot (NYSE:HD) on 6/17/2026.
Purchased $1,001 – $15,000 in shares of Monster Beverage (NASDAQ:MNST) on 6/17/2026.
Sold $1,001 – $15,000 in shares of S&P Global (NYSE:SPGI) on 6/17/2026.
Purchased $1,001 – $15,000 in shares of Meta Platforms (NASDAQ:META) on 6/17/2026.
Purchased $1,001 – $15,000 in shares of SpaceX (NASDAQ:SPCX) on 6/12/2026.

STERIS Stock Performance

STE stock traded down $2.85 during midday trading on Thursday, reaching $227.50. The company had a trading volume of 55,637 shares, compared to its average volume of 777,700. The stock has a 50 day moving average price of $224.83 and a 200 day moving average price of $222.42. STERIS plc has a fifty-two week low of $195.14 and a fifty-two week high of $269.44. The firm has a market capitalization of $22.18 billion, a PE ratio of 27.82 and a beta of 0.91. The company has a quick ratio of 1.35, a current ratio of 1.91 and a debt-to-equity ratio of 0.23.

STERIS (NYSE:STE – Get Free Report) last released its quarterly earnings results on Wednesday, August 5th. The medical equipment provider reported $2.59 EPS for the quarter, topping analysts’ consensus estimates of $2.49 by $0.10. STERIS had a net margin of 13.34% and a return on equity of 14.34%. The company had revenue of $1.49 billion for the quarter, compared to the consensus estimate of $1.49 billion. During the same period in the previous year, the firm earned $2.34 EPS. STERIS’s revenue was up 7.3% on a year-over-year basis. STERIS has set its FY 2027 guidance at 11.000-11.300 EPS. Analysts anticipate that STERIS plc will post 11.09 earnings per share for the current year.

STERIS Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, September 25th. Shareholders of record on Friday, September 4th will be paid a dividend of $0.69 per share. The ex-dividend date is Friday, September 4th. This is a positive change from STERIS’s previous quarterly dividend of $0.63. This represents a $2.76 annualized dividend and a yield of 1.2%. STERIS’s payout ratio is presently 33.74%.

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on STE shares. Wall Street Zen upgraded shares of STERIS from a “hold” rating to a “buy” rating in a research note on Sunday, August 9th. Piper Sandler restated an “overweight” rating and set a $275.00 target price (up from $270.00) on shares of STERIS in a research note on Friday, August 7th. KeyCorp lowered their target price on STERIS from $291.00 to $269.00 and set an “overweight” rating on the stock in a report on Wednesday, May 13th. UBS Group dropped their price target on STERIS from $275.00 to $270.00 and set a “buy” rating on the stock in a research report on Friday, August 7th. Finally, Weiss Ratings reissued a “hold (c)” rating on shares of STERIS in a research report on Monday, August 24th. Three investment analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company. Based on data from MarketBeat, STERIS has a consensus rating of “Moderate Buy” and an average price target of $271.33.

View Our Latest Stock Report on STERIS

Insider Buying and Selling

In related news, VP John Adam Zangerle sold 1,419 shares of STERIS stock in a transaction that occurred on Monday, June 15th. The shares were sold at an average price of $209.28, for a total value of $296,968.32. Following the completion of the sale, the vice president owned 35,259 shares in the company, valued at approximately $7,379,003.52. This trade represents a 3.87% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Mohsen Sohi sold 4,058 shares of the stock in a transaction that occurred on Wednesday, August 12th. The stock was sold at an average price of $235.78, for a total transaction of $956,795.24. Following the sale, the director owned 24,305 shares in the company, valued at approximately $5,730,632.90. This trade represents a 14.31% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders sold 6,851 shares of company stock valued at $1,545,052. Insiders own 1.12% of the company’s stock.

Institutional Investors Weigh In On STERIS

A number of institutional investors have recently added to or reduced their stakes in the stock. Jones Financial Companies Lllp increased its position in shares of STERIS by 46.1% during the 1st quarter. Jones Financial Companies Lllp now owns 1,106 shares of the medical equipment provider’s stock worth $251,000 after purchasing an additional 349 shares during the last quarter. Goldman Sachs Group Inc. raised its holdings in STERIS by 32.3% in the first quarter. Goldman Sachs Group Inc. now owns 242,732 shares of the medical equipment provider’s stock worth $55,015,000 after buying an additional 59,264 shares during the last quarter. Empowered Funds LLC boosted its holdings in STERIS by 16.1% in the first quarter. Empowered Funds LLC now owns 2,303 shares of the medical equipment provider’s stock worth $522,000 after purchasing an additional 319 shares during the last quarter. Woodline Partners LP increased its position in STERIS by 40.0% in the first quarter. Woodline Partners LP now owns 8,300 shares of the medical equipment provider’s stock worth $1,881,000 after buying an additional 2,372 shares in the last quarter. Finally, Jane Street Group LLC lifted its holdings in STERIS by 38.9% in the 1st quarter. Jane Street Group LLC now owns 20,716 shares of the medical equipment provider’s stock worth $4,695,000 after purchasing an additional 5,803 shares in the last quarter. 94.69% of the stock is owned by institutional investors and hedge funds.

About Representative Moskowitz

Jared Evan Moskowitz (Democratic Party) is a member of the U.S. House, representing Florida’s 23rd Congressional District. He assumed office on January 3, 2023. His current term ends on January 3, 2027.

Moskowitz (Democratic Party) is running for re-election to the U.S. House to represent Florida’s 23rd Congressional District. He declared candidacy for the 2026 election.

Jared Evan Moskowitz was born in Coral Springs, Florida. Moskowitz graduated from Marjory Stoneman Douglas High School. He earned a bachelor’s degree in political science and government from George Washington University in 2003 and a law degree from Nova Southeastern University in 2007. Moskowitz’s career experience includes working as the director of the Florida Division of Emergency Management and general counsel with AshBritt Inc.

STERIS Company Profile

(Get Free Report)

STERIS Corporation (NYSE: STE) is a global provider of infection prevention, contamination control and procedural products and services for the healthcare, life sciences, pharmaceutical and medical device industries. The company develops, manufactures and supports a broad portfolio of equipment and consumables designed to reduce risk of infection, maintain sterile environments and support critical clinical and manufacturing procedures.

Its offerings include sterilization and decontamination systems, instrument washers and washers-disinfectors, endoscope reprocessing solutions, surgical equipment and procedural disposables, and contamination-control products for cleanrooms and laboratories.